Novartis | NOVN - Beneficio Operativo





Beneficio Operativo Cambio Fecha
AbbVie USD 4.73B 1.08B 2026-03
Alcon AG USD 297M 16M 2026-03
Almirall EUR 30.23M 12.8M 2025-12
Amgen USD 3.83B 130M 2026-03
AstraZeneca USD 7.11B 4.14B 2026-03
Autolus Therapeutics Ltd USD -59.51M 12.95M 2026-03
Bayer EUR 3.53B 2.42B 2026-03
Biogen USD 514.3M 128.8M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Fresenius EUR 713M 139M 2025-12
Fresenius Medical Care EUR 268M 395M 2026-03
Genmab DKK 260M 199M 2025-12
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
GRIFOLS EUR 249M 26.38M 2026-03
Hikma Pharmaceutical USD 348M 161M 2025-12
J&J USD 6.62B 1.03B 2026-03
Lakefront Biotherapeutics EUR -63.7M 844.26M 2026-03
Lonza CHF 673M 243M 2025-06
Merck EUR 1.05B 572M 2026-03
Merck USD -1.88B 8.12B 2026-03
Novartis USD 4.24B 171M 2026-03
Novartis USD 4.06B 521M 2025-12
Novo Nordisk DKK 59.62B 27.24B 2026-03
Orion EUR 114.8M 213.4M 2026-03
Pfizer USD 4.99B 340M 2026-03
Philips EUR 302M 417M 2026-03
Recordati EUR 231.11M 47.11M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 3.8B 2025-12
Sanofi EUR 1.94B 239M 2026-03
UCB EUR 1.29B 571M 2025-12